Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FWPAYNASDAQ:LSTANASDAQ:MIRANASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFWPAYForward Pharma A/S$300.00$424.38$1.43▼$5.33$6M-42.677 shs11 shsLSTALisata Therapeutics$2.50-2.3%$2.40$1.87▼$4.20$21.55M120,690 shs17,786 shsMIRAMIRA Pharmaceuticals$1.21-2.4%$1.16$0.51▼$5.01$20.47M1.962.21 million shs79,484 shsQTTBQ32 Bio$1.67-1.8%$1.75$1.38▼$53.79$20.37M-0.03200,640 shs154,641 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFWPAYForward Pharma A/S0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics0.00%-7.03%+4.21%+4.64%-27.04%MIRAMIRA Pharmaceuticals0.00%-13.57%-14.79%+2.54%+63.51%QTTBQ32 Bio0.00%-12.11%-4.02%-16.50%-91.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics2.4287 of 5 stars3.53.00.00.02.20.01.3MIRAMIRA Pharmaceuticals3.3285 of 5 stars3.75.00.00.04.10.00.6QTTBQ32 Bio3.4064 of 5 stars3.14.00.00.04.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFWPAYForward Pharma A/S 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$15.00499.76% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.001,057.02% UpsideQTTBQ32 Bio 2.25Hold$24.711,379.90% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics$1M21.55N/AN/A$5.88 per share0.43MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AQTTBQ32 Bio-$6.65M-3.06N/AN/A$22.47 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFWPAYForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALSTALisata Therapeutics-$20.84M-$2.30N/AN/AN/AN/A-51.19%-45.16%8/11/2025 (Estimated)MIRAMIRA Pharmaceuticals-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)QTTBQ32 Bio-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%8/6/2025 (Estimated)Latest FWPAY, MIRA, LSTA, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/A5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFWPAYForward Pharma A/SN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFWPAYForward Pharma A/SN/AN/AN/ALSTALisata TherapeuticsN/A8.038.03MIRAMIRA PharmaceuticalsN/A6.116.11QTTBQ32 Bio0.616.536.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFWPAYForward Pharma A/S2.63%LSTALisata Therapeutics8.94%MIRAMIRA Pharmaceuticals35.16%QTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipFWPAYForward Pharma A/S71.47%LSTALisata Therapeutics9.60%MIRAMIRA Pharmaceuticals6.65%QTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFWPAYForward Pharma A/SN/A20,0007,000Not OptionableLSTALisata Therapeutics308.62 million7.63 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.46 millionNot OptionableQTTBQ32 Bio3912.20 million10.22 millionN/AFWPAY, MIRA, LSTA, and QTTB HeadlinesRecent News About These CompaniesQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataApril 30, 2025 | prnewswire.comLeerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)April 18, 2025 | markets.businessinsider.comQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataApril 16, 2025 | prnewswire.comAll You Need to Know About Q32 Bio (QTTB) Rating Upgrade to BuyApril 8, 2025 | zacks.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)March 12, 2025 | markets.businessinsider.comQ32 Bio price target lowered to $15 from $16 at Wells FargoMarch 12, 2025 | markets.businessinsider.comQ32 Bio Reports Promising Trial Results and FinancialsMarch 12, 2025 | tipranks.comQ32 Bio: Q4 Earnings SnapshotMarch 11, 2025 | sfgate.comQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdateMarch 11, 2025 | prnewswire.comQ32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibartMarch 10, 2025 | markets.businessinsider.comQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingMarch 8, 2025 | prnewswire.comQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingFebruary 28, 2025 | prnewswire.comQ32 Bio to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | prnewswire.comPiper Sandler Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comBMO Capital Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comQ32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News SummaryFebruary 12, 2025 | benzinga.comQ32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitorFebruary 11, 2025 | fiercebiotech.comPiper Sandler cuts Q32 Bio stock rating to neutral, slashes targetFebruary 11, 2025 | msn.comQ32 Bio downgraded to Neutral from Overweight at Piper SandlerFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWPAY, MIRA, LSTA, and QTTB Company DescriptionsForward Pharma A/S NASDAQ:FWPAYForward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.Lisata Therapeutics NASDAQ:LSTA$2.50 -0.06 (-2.30%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$2.41 -0.09 (-3.80%) As of 06/13/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.MIRA Pharmaceuticals NASDAQ:MIRA$1.21 -0.03 (-2.50%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Q32 Bio NASDAQ:QTTB$1.67 -0.03 (-1.76%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
